Volume 93, Issue S255
ABS15-0589
Free Access

Generic Drugs- are they as good as brand-names?

M. Kolko

M. Kolko

Ophthalmology, Roskilde University Hospital, Roskilde, Denmark

Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
N. Ali

N. Ali

Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author
P.K. Jensen

P.K. Jensen

Ophthalmology, Roskilde University Hospital, Roskilde, Denmark

Search for more papers by this author
First published: 23 September 2015

Abstract

Purpose

The aim of the present study was to investigate different characteristics of six Latanoprost generics.

Methods

Prize, drop size and volume in each generic were determined. The hardness of each bottle was further evaluated using a fish weight and a hook. Finally, pH was measured and the buffer capacity evaluated by addition of NaOH.

Results

Price, drop size and volume varied significantly between the brand version (xalatan) and the generic latanoprost products. Hence, drops sized were in the range 40–47 µl and the number of drops in each generic bottle varied between 95 and 111 drops. The embalages of each latanoprost product were different in both size and hardness. The control value of pH in the brand version (Xalatan) was 5.99 ± 0.01 (mean ± SD), whereas the generic latanoprost products had significantly higher values within the range 6.70–6.82. Hence, titration of 2.5 µl Xalatan to neutrality required 70.4 ± 0.4 nmol NaOH compared to the generic latanoprost products which required within the range 28.1–33.7 nmol NaOH.

Conclusions

The present study identifies differences among latanoprost generics such as different pH values and different buffer capacities. Moreover, the emballages varies significantly, thereby leading to critical variations in the handling of the generics. Finally, the number and size of drops in each generic were different, not to mention the prize variations between the brand version and the generics. Over all, generic eye drops should not be considered identical. Therefore, re-evaluation of the requirements for introducing generic drugs seems reasonable.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.